DarioHealth

DarioHealth Corp. is a digital therapeutics company, which engages in the research, development, and sale of pharmaceutical products. It offers a monitoring device, mobile application, and data services for diabetes management. The firm solutions include MyDario, Daro Engage, and Dario Intelligence. The company was founded by Oren Fuerst, Shoshana Friedman, David Weintraub, Dov Oppenheim, and Shilo Ben Zeev on August 11, 2011 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

DarioHealth excels in Q4 2022 with B2B growth and strategic partnerships

DarioHealth's Q4 2022 marked strong financial performance and operational efficiency gains.
Strategic focus on B2B model and multi-condition management driving revenue growth.
Challenges include managing increased expenses and maintaining high gross margin targets.
Opportunities lie in expanding client base, strategic integrations, and revenue diversification.

DarioHealth reports revenue growth and strategic partnerships driving future expansion

DarioHealth's Q1 2023 performance showed revenue growth, improved margins, and strategic focus on B2B.
Strong partnerships with Amwell and Sanofi position the company for multi-condition agreements and revenue growth.
Operational challenges in DTC margins and user comparison require attention for sustained growth.
Opportunities lie in hospitalization reduction, revenue growth from partnerships, and market expansion through Aetna launch.

DarioHealth reports steady Q2 performance, eyes growth through partnerships

DarioHealth's Q2 2023 performance showcased steady B2B2C ARR growth despite flat revenue, with improving gross margins and reduced operating losses, supported by a strong cash position.
The company's strengths lie in strategic partnerships, market fit, and operational efficiency, while facing challenges in revenue growth rates and optimizing expenses.
Opportunities ahead include revenue growth through partnerships and new product launches, leveraging AI for engagement and cost efficiencies, and sustaining a software-driven business model.

DarioHealth reports growth in Q3 2023, eyes revenue diversification

DarioHealth's Q3 2023 showed growth and improved financial metrics.
Strategic partnerships and revenue diversification are key strengths.
Challenges include predicting revenue recognition and cost management.
Opportunities lie in revenue growth and becoming cash flow positive.

DarioHealth reports robust Q4 results, eyes growth through strategic acquisitions

DarioHealth's strong Q4 performance and strategic acquisitions position the company for growth in 2024 and 2025, with a focus on profitability and revenue expansion.
While facing challenges in revenue scaling and cost reduction, the company's strengths in cash position, innovation, and leadership integration provide a solid foundation for success.
Opportunities lie in revenue growth from partnerships and acquisitions, integration synergies, and advancements in digital solutions, driving DarioHealth's path to market differentiation and financial success.

DarioHealth excels in Q1 2024, eyes profitability post Twill merger

DarioHealth's strong Q1 performance driven by B2B2C growth, poised for profitability post Twill merger. Focus on product integration and revenue expansion in key channels.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

DarioHealth Corp. is a digital health company which offers a user-centric and multi-chronic condition digital therapeutics platform that delivers personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain, and behavioral health. DarioHealth serves customers globally. The company was founded by Oren Fuerst, Shoshana Friedman, David Weintraub, Dov Oppenheim, and Shilo Ben Zeev on August 11, 2011 and is headquartered in New York, NY.

First quarter revenue of $ 5.8 million reflects an increase of 59% over fourth quarter of 2023 primarily resulting from an increase in B2B2C revenues and reflects a decrease of 18.5% compared to the first quarter of 2023 due to milestone driven revenues. Core revenue channel B2B2C, employers and health plans recurring revenues in the first quarter totaled $3.47 million, an increase of  176% year over year and 210% sequentially from $1.12 million in the fourth quarter 2023 as the core business continues to gain traction, as well as the addition of Twill Inc. revenues post February 15 th closing Launched the Aetna platform generating revenue in Q1 2024 as Aetna continues to add employers to the platform Accelerated path to profitability through growing revenues in the B2B2C channel which represents proforma of $22M in annual recurring revenue ("ARR") Executing on Dario-Twill synergies that we expect to reduce operating expenses by 30% by the fourth quarter of 2024 Company anticipates reaching a breakeven run rate in the second half of 2025 Ended Q1 2024 with cash equivalents of $34.7 million Company to host investor conference call and webcast at 8:30 a.m.

DarioHealth Reports First Quarter 2024 Financial and Operating Results

Company to host conference call and webcast at 8:30am ET NEW YORK , May 7, 2024 /PRNewswire/ --  DarioHealth Corp. (Nasdaq: DRIO), a leader in the global digital therapeutics (DTx) market, announced today that it will release its financial results for the 1st quarter ended March 31st, 2024, on Wednesday, May 15th, 2024, before the market opens and will host a conference call and webcast at 8:30 am Eastern Time. Erez Raphael, Chief Executive Officer and Rick Anderson, President, will host the call.

DarioHealth to Report First Quarter 2024 Results on Wednesday, May 15th

Quasi-randomized study demonstrates the value of Dario's integrated approach to provide one solution for members to manage diabetes, pre-diabetes, blood pressure, weight and taking a GLP-1 NEW YORK , April 25, 2024 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO) ("Dario" or the "Company"), a leader in the global digital health market, announced today new research published in the leading peer-reviewed journal for digital health and medicine, Journal of Internet Medicine (JMIR) demonstrating a clinically significant reduction in blood glucose levels for members using Dario to manage weight alongside diabetes. More than 80% of people living with Type 2 diabetes are overweight and the two conditions are closely linked to the same underlying unhealthy behaviors.

Dario Publishes New Peer-Reviewed Study that Deepens the Body of Evidence that Managing Cardiometabolic Conditions in One Integrated Platform Improves Clinical Outcomes

Dario selected to provide integrated and proven solutions to improve employee cardiometabolic health NEW YORK , April 18, 2024 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO) ("Dario" or the "Company"), a leader in the global digital health market, announced today two new contracts to provide integrated chronic condition management solutions for two employers beginning in the second quarter of 2024. The employers, a national supply chain company and a regional education organization, selected Dario's cardiometabolic suite to help improve outcomes for employees with cardiometabolic health conditions, including diabetes, pre-diabetes, hypertension and weight management needs, including support for individuals taking a GLP-1 medication.

Dario Signs Two Employers for Cardiometabolic Suite with Integrated GLP-1 Solution

Studies include a Randomized Controlled Trial demonstrating significant reduction in perceived stress for teens NEW YORK , April 10, 2024 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO) ("Dario" or the "Company"), a leader in the global digital health market, announced today two new studies published in the leading peer-reviewed journal for digital health and medicine, Journal of Internet Medicine (JMIR), including a Randomized Controlled Trial (RCT) demonstrating the impact of a digital stress reduction program for teens. Digital Tools Reduce Stress and Brooding in Teens in a Randomized Control Trial The first study uses the gold standard in research, a randomized controlled clinical trial (RCT), to demonstrate the impacts of a self-guided Digital Mental Health Intervention (DMHI) for teens.

Dario Publishes Two New Peer-Reviewed Studies Demonstrating Impact of Digital Behavioral Health

Dario selected to provide integrated approach to improve employee cardiometabolic health - including support for those taking a GLP-1 medication - musculoskeletal and behavioral health NEW YORK , April 2, 2024 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO) ("Dario" or the "Company"), a leader in the global digital health market, announced today two new contracts to provide integrated chronic condition management solutions for two national employers beginning in the second quarter of 2024.   The first employer, a global private investment group, selected Dario's cardiometabolic suite to help improve outcomes for employees with cardiometabolic health conditions, including diabetes, pre-diabetes, hypertension and weight management needs, including support for individuals taking a GLP-1.

Two National Employers Select Dario's Integrated Chronic Condition Solution to Improve Employee Health

DarioHealth Corp. (DRIO) Q4 2023 Earnings Call Transcript

Full-year 2023 revenue of $20.4 million reflects a decrease from 2022 revenue of $7.3 due to a managed decrease in B2C and strategic milestone revenue as the core B2B2C revenue increased. 2023 B2B2C, employers and health plans recurring revenues increased 39% year over year as the core business continues to gain traction.

DarioHealth Reports Fourth Quarter and Full-Year 2023 Financial and Operating Results

Company to host conference call and webcast at 8:30am ET NEW YORK , March 21, 2024 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a leader in the global digital therapeutics (DTx) market, announced today that it will release its financial results for the 4th quarter ended December 31, 2023, on Thursday, March 28th, 2024, before the market opens and will host a conference call and webcast at 8:30 am Eastern Time. Erez Raphael, Chief Executive Officer and Rick Anderson, President, will host the call.

DARIOHEALTH TO REPORT FOURTH QUARTER 2023 RESULTS ON THURSDAY, MARCH 28TH

Study presented at ATTD 2024 is the first of a planned series examining the impact of Dario's integrated cardiometabolic solution as a means to address weight and diabetes with or without a GLP-1 Additional research presented demonstrated Dario's ability to improve awareness of the importance of flu vaccines in member with Type 2 diabetes NEW YORK , March 12, 2024 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO) (the "Company"), a leader in the global digital therapeutics (DTx) market, announced today two new clinical studies presented at the 17th International Conference on Advanced Technologies and Treatments for Diabetes (ATTD) 2024, held March 6 – 9 in Florence, Italy. Examining evolving standards for metabolic health: Improving outcomes with or without medication The introduction of GLP-1s as an effective tool for both weight loss and diabetes management is evolving the standards of care for metabolic health conditions.

New Research from Dario Demonstrates Ability to Deliver Improved Health Outcomes with Integrated Solution for Members Managing Weight and Blood Glucose with or without GLP-1 Medications

NEW YORK, Feb. 28, 2024 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a leader in the global digital health market, today announced that management will participate in the Cowen 44th Annual Healthcare Conference, which is being held March 4-6, 2024, at the Boston Marriott Copley Place in Boston, Massachusetts. Erez Raphael, Chief Executive Officer, and Rick Anderson, President, will participate in a fireside chat on Wednesday, March 6th, from 10:30 – 11:00 AM ET.

DARIOHEALTH TO PARTICIPATE IN THE COWEN 43RD ANNUAL HEALTHCARE CONFERENCE

Data Storage Corp

Janover Inc

La Rosa Holdings Corp

Sacks Parente Golf Inc

Six Top MicroCap CEOs To Watch Live RALEIGH, NC / ACCESSWIRE / February 21, 2024 / On the second day of our virtual conference, the CEOs of the following companies will present: 10:00 AM EST La Rosa Holdings / NASDAQ:LRHC - you can view presentation here 10:30 AM EST Janover Inc. / NASDAQ:JNVR - you can view presentation here 11:30 AM EST Base Carbon Inc. / OTCQX:BCBNF - you can view presentation here 1:00 PM EST Data Storage Corp. / NASDAQ:DTST - you can view presentation here 1:30 PM EST SPG Sacks Parente Golf / NASDAQ:SPGC - you can view presentation here 2:00 PM EST Dario Health Corp. / NASDAQ:DRIO - you can watch presentation here For more information go to www.microcaprodeo.com About the MicroCap Rodeo Conference: The MicroCap Rodeo Winter Wrap Up Conference is unique, as it is run by money managers and investors for money managers and investors. Throughout a 4-day period, investors can harness top stock ideas for their portfolios.

Today's Schedule at The MicroCap Rodeo Winter Wrap Up Conference

Expecting nearly doubling Dario's pro forma revenues in 2023 Acquisition is immediately accretive to revenue and gross margins and expected to accelerate path to profitability Concurrent with the acquisition Dario prices $22.4 million equity financing Company to host conference call today at 8:30am ET. Dial-in and replay information below NEW YORK , Feb. 21, 2024 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO) ("Dario" or the "Company") announced today that it has acquired Twill, Inc. ("Twill"), a leader in digital-led care.

Dario acquires Twill creating one of the most comprehensive digital health platform across the most prevalent chronic conditions

Dario's integrated solution to support improved whole health gains traction in public and labor market NEW YORK , Jan. 11, 2024 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO) ("Dario" or the "Company"), a leader in the global digital health market, announced today a new contract to provide its cardiometabolic solution to a regional union (the "Union"), expected to begin in the first quarter of 2024.   The Union, representing food industry workers, selected Dario to deliver integrated support for employees living with diabetes, pre-diabetes and weight management needs along with special support for those taking a GLP-1, or anti-obesity medication.

Regional Union Selects Dario's Cardiometabolic Solution for Diabetes, Hypertension, Weight Management and GLP-1 Support

New client will use Dario's integrated approach to support long-term behavior change for employees living with diabetes, pre-diabetes, hypertension and those taking a GLP-1 medication NEW YORK , Dec. 5, 2023 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO) ("Dario" or the "Company"), a leader in the global digital health market, announced today a new contract to provide cardiometabolic and GLP-1 solutions to a national employer (the "Employer") beginning in January 2024.   The Employer, a national logistics company, selected Dario to deliver integrated support for employees living with diabetes, pre-diabetes, weight management and hypertension, while also providing a tailored experience for employees taking a GLP-1 medication.

National Employer Selects Dario Cardiometabolic and GLP-1 Solutions to Improve Employee Health

Nonprofit health plan expands services to better meet the healthcare needs of Californians by making it easier to enroll in lifestyle medicine programs at no additional cost OAKLAND, Calif. , Nov. 29, 2023 /PRNewswire/ -- Blue Shield of California is making its award-winning digital health platform Wellvolution more accessible for Spanish-speakers and expanding its program with the addition of Dario, an at-home solution for high blood pressure, or hypertension, that combines personalized health coaching and tech-enabled monitoring.

Blue Shield of California's Award-Winning Wellvolution Now More Accessible for Spanish Speakers, Adds New Hypertension Offering

Demand for Dario's integrated cardiometabolic solution continues to grow as employers grappling with the surge in GLP-1 medication utilization search for proven ways to change health behaviors NEW YORK , Nov. 27, 2023 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO) ("Dario" or the "Company"), a leader in the global digital health market, announced today a new contract to provide its cardiometabolic solution to an employer (the "Employer") beginning in January 2024.     The Employer, a national financial and business services company, selected Dario to improve the cardiometabolic health of its population with an integrated solution for diabetes, pre-diabetes, weight management and hypertension along with tailored support for employees taking a GLP-1, or anti-obesity, medications.

Dario Contracts with New Employer for Cardiometabolic Solution

Two new analyses associate improved clinical and economic outcomes with use of Dario's digital health solution NEW YORK , Nov. 21, 2023 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO) ("Dario" or the "Company"), a leader in the global digital health market, announced today two new analyses recently presented by Sanofi U.S. demonstrating two mediators associated with improved clinical and economic in Dario users. Improved Clinical Outcomes Linked with Improved Medication Adherence Presentations by Sanofi U.S. at the Diabetes Technology Society (DTS) annual conference, held Nov. 2 – 4, examined real-world data from matched Dario users and non-users with type 2 diabetes to determine the association of medication adherence from Dario's digital health solution with blood glucose control.

New Research Sheds Light on Mediators of Improved Outcomes in Dario Users

New study highlights the value of a whole health approach managing chronic conditions and supporting members using GLP-1s NEW YORK , Nov. 13, 2023 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO) ("Dario" or the "Company"), a leader in the global digital health market, announced new research presented at the Diabetes Technology Society 2023 Meeting on November 7, 2023. The new research demonstrated the value of associating physical activity tracking alongside blood sugar tracking for people living with diabetes and pre-diabetes.

Dario Publishes New Research Demonstrating that Dario Users That Increased Physical Activity Can Maintain Reduced Blood Glucose

Third quarter total revenue of $3.52 million compared to $6.6 million in the third quarter of 2022, impacted mainly by lower commercial strategic partners revenues in the quarter of $209,000 as compared to $3.1 million in Q3 2022.  Third quarter 2023 commercial B2B2C revenues from monthly recurring revenues derived from employers and health plans is up 19.3% over third quarter 2022; nine months YTD up 57% over comparable period in 2022.

DarioHealth Reports Third Quarter 2023 Financial and Operating Results

New connectivity expands Dario's advantage with consumer accessibility NEW YORK , Nov. 1, 2023 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO) ("Dario" or the "Company"), a leader in the global digital health market, announced the launch of a new smart blood sugar meter for Apple iPhone 15 users to support ongoing engagement with new and existing members.     As recently reported, the new iPhone 15 is built with a USB-C charging port, a key element for real-time data capture in Dario's smart blood glucose meter.

Dario Launches Apple iPhone 15 Accessible Smart Blood Glucose Meter

Company to host conference call and webcast at 8:30am ET NEW YORK , Oct. 30, 2023 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a leader in the global digital health market, today announced that it will release its financial results for the third quarter ended September 30, 2023, on Thursday, November 2, 2023, before market opens and will host a conference call and webcast at 8:30 am Eastern Time. Erez Raphael, Chief Executive Officer and Rick Anderson, President, will host the call.

DarioHealth to Report Third Quarter 2023 Results on Thursday, November 2nd

New research demonstrates Dario's ability to reduce costs through lower utilization of expensive healthcare resources, and the winning of a prestigious gold ribbon award NEW YORK , Oct. 17, 2023 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO) ("Dario" or the "Company"), a leader in the global digital health market, announced today new research presented by Sanofi U.S. at the Academy of Managed Care Pharmacy's 2023 annual conference Nexus ("AMCP-Nexus"), demonstrating a 36% reduction in 30-day hospital readmissions for Dario users compared to non-users living with type 2 diabetes.   Research Demonstrates Significant Reductions in Costly Utilization Metrics New data presented by Sanofi U.S. at AMCP-Nexus examined matched Dario users and non-users with type 2 diabetes to understand the impact of Dario's digital health solution.

New Research Shows 36% Reduction in 30-Day Hospital Readmission Rate for Dario Users with Type 2 Diabetes

Agreement names Dario as the preferred digital health provider for employer clients NEW YORK , Oct. 5, 2023 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO) ("Dario" or the "Company"), a leader in the global digital health market, announced a new strategic partnership with a top five national employee benefits consulting firm (the "Firm"), to become the preferred digital health and chronic condition solution partner for its national employer clients. The Firm selected Dario for its proven ability to deliver meaningful engagement and improved clinical results at a lower cost than competitors.

Dario Signs National Preferred Partner Agreement with a Top Five National Employee Benefits Consulting Firm

In-person event scheduled for Tuesday, October 17, 2023, in New York NEW YORK , Oct. 3, 2023 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO) ("Dario" or the "Company"), a leader in the global digital health market, announced that it will host an in-person investor day in New York at the offices of Sullivan & Worcester LLP located at 1633 Broadway, 32nd floor, on October 17, 2023 at 11:00 AM ET.   To attend the in-person event, you must pre-register by clicking here.

News for DarioHealth Stock (DRIO)